LSIL, Low Grade Squamous Intraepithelial Lesion
3 clinical trials · Condition
◉ Watch LSIL, Low Grade Squamous Intraepithelial Lesion
| Record | Firm | Date |
|---|---|---|
| Phase II Study of Dysplasix™ Intravaginal Suppositories in Patients Patients With High-Risk HPV and Mild Cervical Cytologic Abnormalities (NCT07572396) | Amplexd Therapeutics, Inc. | 2026-04-30 |
| Multicenter Prospective Non-randomized Controlled Study of ALA-PDT for LSIL With HPV16/18 Infection (NCT07306247) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2026-01-01 |
| Evaluation Of The Efficacy Of The Combination Of GLIZIGEN® Oral Solution 1/Day And Vaginal Gel 1/Night For 2 Months In Patients With Cervical Intraepithelial Neoplasia Grade 1 (LSIL/CIN-1) Caused By High-Risk Human Papillomavirus (HPV-AR) (NCT05916911) | Catalysis SL | 2023-06-07 |
Track LSIL, Low Grade Squamous Intraepithelial Lesion automatically
Every clearance here is in the API, with alerts when new ones post.